Vifor Pharma sells OM Pharma to Optimus

18 September 2020

Swiss drugmaker Vifor Pharma (VTX: VIF0N) today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding. The terms of the deal include:

A purchase consideration of 435 million Swiss francs ($480 million) for 100% of the share capital; and
An earn out related to potential future value gains on 20% of Optimus Holding equity to be determined before the end of 2027 upon a trade sale, initial public offering (IPO) or earnings before interest, taxes, depreciation and amortization (EBITDA) multiple

This earn out together with the purchase consideration could result in a total transaction value exceeding 500 million francs. The deal is expected to close within 30 days.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK